ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCYC vs QTTB // 10Y YIELD & FRED MACRO BETA

Bicycle Therapeutics plc (NASDAQ) VS. Q32 Bio Inc. (NASDAQ) • 15-METRIC TALLY: BCYC 1 — QTTB 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCYC VS. QTTB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCYC QTTB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 QTTB /roic <GO>
EV/EBITDA & P/E Valuation — 12.8x — TIE /valuation <GO>
Free Cash Flow Yield — -12.70% — TIE /fcf-yield <GO>
Operating Margin -60.00% 31.50% -91.50 QTTB /operating-margins <GO>
Net Profit Margin -60.00% 55.50% -115.50 QTTB /net-margins <GO>
Revenue Growth (YoY) 105.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.99 -5.79 QTTB /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 QTTB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.1 48.1 -0.05 QTTB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 8.3x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $267.4M $264.1M $3.3M BCYC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCYC REV QTTB REV BCYC GROSS % QTTB GROSS % BCYC FCF QTTB FCF
FY 2025 $72.6M $53.7M — — -$252.0M -$33.5M
FY 2024 $35.3M $0 — — -$166.0M -$67.8M
FY 2023 $27.0M $1.2M — — -$60.6M -$18.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCYC // BETA —
QTTB // BETA —